MedTrace Logo

A Study of the Next-generation Probiotic, Veillonella Atypica FB0054 vs Placebo

NCT06141343 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 153

Last updated 2023-11-21

No results posted yet for this study

Summary

In this study, the investigators are assessing the ability of Veillonella (Veillonella atypica FB0054) to decrease fatigue and increase energy in a heterogeneous cohort of healthy adults compared to placebo. Study subjects will fill out a baseline health and habit survey followed by daily and weekly surveys over a two week baseline period to understand their baseline habits, fatigue, and energy levels. After this, subjects will take one daily capsule orally of one of two doses of Veillonella or placebo for four weeks, while again filling out both daily and weekly surveys. Finally, there will be a two week washout period with no supplementation but only daily and weekly surveys. At the end of the study, there will be a final experience survey.

Conditions

Interventions

DIETARY_SUPPLEMENT

Veillonella atypica FB0054

Veillonella contains Veillonella atypica FB0054 as the active ingredient with microcrystalline cellulose and hypromellose as excipients. The two doses are 15 billion cfu (high dose) and 7.5 billion cfu (low dose). Placebo capsules contain microcrystalline cellulose and hypromellose. Both Veillonella and placebo are encapsulated in acid-resistant capsules to improve delivery to the large intestine, which participants will take orally at home on a daily basis for four weeks.

OTHER

Placebo

Placebo will be given as the non-active study control

Sponsors & Collaborators

  • People Science, Inc.

    collaborator INDUSTRY

  • FitBiomics, Inc.

    lead INDUSTRY

Principal Investigators

  • Jonathan Scheiman, PhD · FitBiomics, Inc.

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2023-11-07
Completion
2023-11-07

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06141343 on ClinicalTrials.gov